Il punto su
Glomerulopatia da depositi di C3
C3-glomerulopathy - What should paediatricians know
Stefano Amoroso1, Marco Pennesi2, Alessandro Ventura1,2
1Università di Trieste
2IRCCS Materno-Infantile “Burlo Garofolo”, Trieste
Febbraio 2018
Abstract
C3-glomerulopathy includes several nephropathy charac-terised by almost only C3 deposits without immunoglobu-lins with a mesangial proliferative or membrano-proliferative pattern on light microscopy. C3-glomerulopathy is determined by a dysregulation of the al-ternative pattern of complement due to autoantibodies such as C3 nephritic factor or mutations of complement pro-teins. Corticosteroids combined with mofetil micofenolate could be effective in inducing a partial or complete remis-sion. Eculizumab, the humanised monoclonal antibody di-rected against C5, has been shown to have a favourable effect in several case series of patients.
Contenuto riservato
Per leggere l'articolo è necessario effettuare il login.
Per l'acquisto del singolo articolo scrivi a
abbonamenti@medicoebambino.com
(la mail si prepara da sola con gli estremi dell'articolo);
se accedi, la richiesta parte con un click.
Classificazione MeSH
Bibliografia
- Cook HT. C3 glomerulopathy. F1000Res 2017;6:248.
- Riedl M, Thorner P, Licht C. C3 glomerulopathy. Pediatr Nephrol 2017;32(1):43-57.
- Nester CM, Smith RJ. Complement inhibition in C3 glomerulopathy. Semin Immunol 2016;28(3):241-9.
- O’Flynn J, Flierman R, van der Pol P, et al. Nucleosomes and C1q bound to glomerular endothelial cells serve as targets for autoantibodies and determine complement activation. Mol Immunol 2011;49(1-2):75-83.
- Weening JJ, D’Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004;15(2):241-50.
- Lioufas N, Finlay M, Barbour T. Durable remission of C3 glomerulonephritis with mycophenolate mofetil. Nephrology (Carlton) 2017;22(suppl 1):36-9.
- Rabasco C, Cavero T, Roman E, et al.; Spanish Group for the Study of Glomerular Diseases (GLOSEN). Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int 2015;88(5):1153-60.
- Payette A, Patey N, Dragon-Durey MA, Frémeaux-Bacchi V, Le Deist F, Lapeyraque AL. A case of C3 glomerulonephritis successfully treated with eculizumab. Pediatr Nephrol 2015;30(6):1033-7.
- Lebreton C, Bacchetta J, Dijoud F, Bessenay L, Fremeaux-Bacchi V, Sellier-Leclerc AL. C3 glomerulopathy and eculizumab: a report on four paediatric cases. Pediatr Nephrol 2017;32:1023-8.